Animas Corporation, part of the Johnson & Johnson Diabetes Care Companies, announced today that it has received U.S. Food and Drug Administration (FDA) approval, and Health Canada’s authorization for the sale of the OneTouch Vibe™ Plus Insulin Pump and Continuous Glucose Monitoring System for the treatment of patients age two
We’re looking ahead to some innovative medical devices arriving in 2017 and beyond—namely, a series of ‘artificial organs’ that imitate a key bodily function.
Insulet, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System today announced it has reached a milestone of 100,000 global users enjoying the quality of life benefits of the Omnipod System.
“White hat” hackers can test cyber vulnerabilities of connected medical devices without fear of legal repercussion.
Johnson & Johnson is warning customers that its Animas OneTouch Ping Insulin pump can be hacked—a cybersecurity vulnerability that could be deadly.
Many companies in the life science space are looking for ways to help people with diabetes, and one area in which big strides are currently being made is diabetes testing. Companies involved in the space are looking at different ways of testing and monitoring blood sugar, and even at pre-screening
Insulet Corporation (NASDAQ:PODD), which has a tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc. (NASDAQ:AMGN) for a 5-year commercial agreement to supply Amgen with a delivery device designed around the delivery needs of biotechnology medicines.
Alex Daley, senior editor of Casey Extraordinary Technology, seeks out undiscovered names because that’s where he finds the big upside. In this interview with The Life Sciences Report, Daley brings his best ideas to investors who won’t shy away from unloved biotech and medtech names. Sharpen your pencils, steel your